Newer Therapies for Bacterial and Fungal Infections

Dear Colleagues,

In recent decades, the widespread use of antimicrobials to control infections caused by bacteria and fungi has led to the development of strains resistant to available therapeutic agents. Microbial resistance can occur rapidly through spontaneous mutations in chromosomal DNA or transfer of genetic elements via plasmids or transposons. The increased resistance profile, associated with the low number of new antimicrobials approved for clinical use, represents a major threat to public health worldwide.

In 2019, the drug resistance pathogens were classified by the U.S. Centers for Disease Control and Prevention (CDC) as urgent threats (carbapenem-resistant Acinetobacter, Candida auris, Clostridioides difficile, carbapenem-resistant Enterobacterales, drug-resistant Neisseria gonorrhoease), serious threats (drug-resistant Campylobacter, drug-resistant Candida, ESBL-producing Enterobacterales, vancomycin-resistant Enterococci, multidrug-resistant Pseudomonas aeruginosa, drug-resistant nontyphoidal Salmonella, drug-resistant Salmonella serotype Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus, drug-resistant Streptococcus pneumoniae, drug-resistant tuberculosis), and concerning threats (erythromycin-resistant Group A Streptococcus, clindamycin-resistant Group B Streptococcus).

Therefore, the search for new therapies for the treatment of infectious diseases is one of the main challenges of the 21st century. This Special Issue welcomes submissions of studies focused on new therapeutic options for bacterial and fungal infections, such as the synthesis of antimicrobial compounds, drug repurposing, photodynamic therapy, and drug delivery systems.

We look forward to receiving your contributions.

Dr. Juliana Campos Junqueira
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.